Axsome Therapeutics (AXSM) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.99
- EPS estimate
- −$0.89
- EPS surprise
- −10.97%
- Revenue surprise
- −2.15%
- Revenue
- $216.4M
- Revenue estimate
- $221.1M
- Reported
- Aug 10, 2026
Axsome Therapeutics reported Q2 2026 results on August 10, 2026. It posted a loss of $0.99 per share, wider than the expected loss of $0.89, a miss of 10.97%. Revenue was $216.4 million, slightly below the $221.1 million estimate. Compared with Q2 2025, revenue rose about 44% from $150.0 million, while the loss per share was close to the year-earlier $0.97.
Every quarter in the table, back to Q3 2021, was a loss. The annual loss per share was $4.57 in 2022, $5.20 in 2023 and $5.99 in 2024, then narrowed to $3.69 in 2025. The first half of 2026 adds up to a loss of $2.25. Revenue has grown from $8.8 million in Q2 2022 to the latest $216.4 million, the highest in the table. Annual revenue rose from $270.6 million in 2023 to $384.7 million in 2024 and $637.2 million in 2025. Axsome beat the EPS estimate in seven of the last 20 quarters and missed in 13.
Axsome reported Q3 between November 3 and November 12 in each of the past five years. That points to early or mid-November 2026 for the next report. It will show whether revenue keeps rising and how the loss compares.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 10, 2026 | −$0.89 | −$0.99 | −10.97% | $216.4M | SEC |
| Q1 2026 | May 4, 2026 | −$0.81 | −$1.26 | −54.70% | $189.4M | SEC |
| Q4 2025 | Feb 23, 2026 | −$0.69 | −$0.56 | +19.13% | $194.7M | SEC |
| Q3 2025 | Nov 3, 2025 | −$0.86 | −$0.94 | −9.15% | $171.0M | SEC |
| Q2 2025 | Aug 4, 2025 | −$1.06 | −$0.97 | +8.07% | $150.0M | SEC |
| Q1 2025 | May 5, 2025 | −$1.35 | −$1.22 | +9.71% | $121.5M | SEC |
| Q4 2024 | Feb 18, 2025 | −$1.00 | −$1.54 | −53.85% | $118.8M | SEC |
| Q3 2024 | Nov 12, 2024 | −$1.38 | −$1.34 | +3.14% | $103.7M | SEC |
| Q2 2024 | Aug 5, 2024 | −$1.31 | −$1.67 | −27.76% | $87.2M | SEC |
| Q1 2024 | May 6, 2024 | −$1.20 | −$1.44 | −19.55% | $75.0M | SEC |
| Q4 2023 | Feb 20, 2024 | −$1.17 | −$2.08 | −77.57% | $71.5M | SEC |
| Q3 2023 | Nov 6, 2023 | −$1.20 | −$1.32 | −9.70% | $57.8M | SEC |
| Q2 2023 | Aug 7, 2023 | −$1.21 | −$1.54 | −26.91% | $46.7M | SEC |
| Q1 2023 | May 8, 2023 | −$1.30 | −$0.26 | +80.06% | $94.6M | SEC |
| Q4 2022 | Feb 27, 2023 | −$1.13 | −$1.41 | −25.23% | $24.4M | SEC |
| Q3 2022 | Nov 7, 2022 | −$1.05 | −$1.07 | −1.90% | $16.8M | SEC |
| Q2 2022 | Aug 9, 2022 | −$1.01 | −$1.06 | −5.36% | $8.8M | SEC |
| Q1 2022 | May 2, 2022 | −$1.00 | −$1.03 | −2.72% | $0.00 | SEC |
| Q4 2021 | Mar 1, 2022 | −$1.02 | −$0.90 | +11.89% | $0.00 | SEC |
| Q3 2021 | Nov 8, 2021 | −$0.95 | −$0.93 | +2.50% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Axsome Therapeutics (AXSM) last report earnings?
Axsome Therapeutics last reported on Aug 10, 2026, covering fiscal Q2 2026.
Did AXSM beat earnings estimates?
No. Axsome Therapeutics reported EPS of −$0.99 for Q2 2026 against a −$0.89 estimate — a 10.97% miss.
How much revenue did AXSM report last quarter?
Axsome Therapeutics reported $216.4M in revenue for Q2 2026, against a consensus estimate of $221.1M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.